ReviewMetabolites2018
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives.
Review in Metabolites, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Novel therapeutic strategies targeting mitochondrial quality control for metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2026Review
- Metabolomic Profiling of Hepatitis B-Associated Liver Disease Progression: Chronic Hepatitis B, Cirrhosis, and Hepatocellular Carcinoma.Metabolites · 2025Article
- [Regulatory effect ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Association of Nonalcoholic Fatty Liver Disease with Arterial Stiffness and its Metabolomic Profiling in Japanese Community-Dwellers.Journal of atherosclerosis and thrombosis · 2024Article
- Integrated multi-omics and bioinformatic methods to reveal the mechanisms of sinomenine against diabetic nephropathy.BMC complementary medicine and therapies · 2023Article
- Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease.Metabolites · 2023Review
- Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD.Frontiers in endocrinology · 2023Article
- Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis.World journal of hepatology · 2022Review
- Clinical Phenotyping and the Application of Precision Medicine in MAFLD.Clinical liver disease · 2022Review
- Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis.Nutrition & diabetes · 2022Article
- Non-invasive assessment of metabolic dysfunction-associated fatty liver disease.Therapeutic advances in endocrinology and metabolism · 2022Review
- Gut microbiota-mitochondrial inter-talk in non-alcoholic fatty liver disease.Frontiers in nutrition · 2022Review
- Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by TargetedMetabolites · 2021Article
- Serum aromatic and branched-chain amino acids associated with NASH demonstrate divergent associations with serum lipids.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- Article
- San-Huang-Yi-Shen Capsule Ameliorates Diabetic Nephropathy in Rats Through Modulating the Gut Microbiota and Overall Metabolism.Frontiers in pharmacology · 2021Article
- Early detection of metabolic changes in drug-induced steatosis using metabolomics approaches.RSC advances · 2020Article
- Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats.Nutrients · 2020Article
- Metabonomic Profile of Macrosteatotic Allografts for Orthotopic Liver Transplantation in Patients With Initial Poor Function: Mechanistic Investigation and Prognostic Prediction.Frontiers in cell and developmental biology · 2020Article
- Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.World journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, metabolomics has attracted great scientific attention. The metabolomics methodology might permit a view into transitional phases between healthy liver and nonalcoholic steatohepatitis. Metabolomics can help to analyze the metabolic alterations that play a main role in the progression of nonalcoholic steatohepatitis. Lipid, glucose, amino acid, and bile acid metabolism should be widely studied to understand the complex pathogenesis of nonalcoholic steatohepatitis. The discovery of new biomarkers would be important for diagnosis and staging of liver disease as well as for the assessment of efficacy of new drugs. Here, we review the metabolomics data regarding nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. We analyzed the main studies regarding the application of metabolomics methodology in the complex context of nonalcoholic steatohepatitis, trying to create a bridge from the basic to the clinical aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.